[ad_1]
Geneva, Switzerland and Boston, MA – 22 February 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of new treatments for serious diseases compromising reproductive health and the pregnancy of a woman, announced today That the company's management would attend two upcoming investor conferences.
- The SVB Leerink World Healthcare Conference will be held in New York from February 27 to March 1, 2019. ObsEva will be presenting its work on Thursday, February 28, 2019 at 3 pm Eastern Time.
- The Jefferies Global Healthcare Summit will be held in Zurich, Switzerland on March 8, 2019. ObsEva will be presenting on Friday, March 8, 2019 at 3:45 pm. Central European time.
SVB Leerink's presentation will be webcast and available in the "Investors" section of the ObsEva website. www.ObsEva.com.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of new treatments for serious diseases that compromise reproductive health and the pregnancy of a woman. Through internal strategic licensing and disciplined drug development, ObsEva has implemented an advanced stage clinical pipeline including developmental programs focused on the treatment of endometriosis, uterine fibroids, premature labor and stroke. 39, improved results of IVF. ObsEva is listed on the NASDAQ Global Select Market and trades under the symbol "OBSV" and on the SIX Swiss Exchange, where it trades under the symbol "OBSN". For more information, please visit www.ObsEva.com.
For more information, please contact:
Press contact Switzerland and Europe:
Christophe lamps
Dynamic Group
[email protected]
+41 22 308 6220 Office
+41 79 476 26 87 Mobile
Media Contact U.S .:
Marion Janic
RooneyPartners LLC
[email protected]
+1 212 223 4017 Office
+1 646 537 5649 Mobile
Contact of the CEO's office:
Shauna Dillon
[email protected]
+41 22 552 1550
Investor contact:
Mario Corso
Senior Director, Investor Relations
[email protected]
+1 857 972 9347 Office
+1 781 366 5726 Mobile
Source link
